PL428534A1 - Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna ją zawierająca - Google Patents

Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna ją zawierająca

Info

Publication number
PL428534A1
PL428534A1 PL428534A PL42853419A PL428534A1 PL 428534 A1 PL428534 A1 PL 428534A1 PL 428534 A PL428534 A PL 428534A PL 42853419 A PL42853419 A PL 42853419A PL 428534 A1 PL428534 A1 PL 428534A1
Authority
PL
Poland
Prior art keywords
composition containing
active substances
pharmaceutical
pharmaceutical composition
carrier
Prior art date
Application number
PL428534A
Other languages
English (en)
Other versions
PL245223B1 (pl
Inventor
Paweł BIERNAT
Jan MELER
Original Assignee
Biotts Spółka Akcyjna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotts Spółka Akcyjna filed Critical Biotts Spółka Akcyjna
Priority to PL428534A priority Critical patent/PL245223B1/pl
Priority to BR112021013680-0A priority patent/BR112021013680A2/pt
Priority to CN202080008696.6A priority patent/CN113301887A/zh
Priority to EP20738497.5A priority patent/EP3908320A4/en
Priority to US17/420,133 priority patent/US12478679B2/en
Priority to JP2021540520A priority patent/JP7654549B2/ja
Priority to PCT/PL2020/050003 priority patent/WO2020145833A1/en
Priority to CA3126384A priority patent/CA3126384C/en
Publication of PL428534A1 publication Critical patent/PL428534A1/pl
Publication of PL245223B1 publication Critical patent/PL245223B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Przedmiotem wynalazku jest nośnik farmaceutyczny dla substancji czynnych charakteryzujący się tym, że zawiera silnie solwatujący rozpuszczalnik aprotyczny z grupy sulfotlenków, amid kwasu węglowego, oraz olej roślinny o dużej zawartości nienasyconych kwasów tłuszczowych oraz kompozycja farmaceutyczna zawierająca nośnik.
PL428534A 2019-01-10 2019-01-10 Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna go zawierająca PL245223B1 (pl)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PL428534A PL245223B1 (pl) 2019-01-10 2019-01-10 Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna go zawierająca
BR112021013680-0A BR112021013680A2 (pt) 2019-01-10 2020-01-10 Veículo farmacêutico para substâncias ativas e uma composição farmacêutica contendo o referido veículo
CN202080008696.6A CN113301887A (zh) 2019-01-10 2020-01-10 用于活性物质的药物载体和包含所述载体的药物组合物
EP20738497.5A EP3908320A4 (en) 2019-01-10 2020-01-10 Pharmaceutical carrier for active substances and a pharmaceutical composition containing said carrier
US17/420,133 US12478679B2 (en) 2019-01-10 2020-01-10 Pharmaceutical carrier for active substances and a pharmaceutical composition containing said carrier
JP2021540520A JP7654549B2 (ja) 2019-01-10 2020-01-10 活性物質のための医薬担体および前記担体を含有する医薬組成物
PCT/PL2020/050003 WO2020145833A1 (en) 2019-01-10 2020-01-10 Pharmaceutical carrier for active substances and a pharmaceutical composition containing said carrier
CA3126384A CA3126384C (en) 2019-01-10 2020-01-10 Pharmaceutical carrier for active substances and a pharmaceutical composition containing said carrier

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL428534A PL245223B1 (pl) 2019-01-10 2019-01-10 Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna go zawierająca

Publications (2)

Publication Number Publication Date
PL428534A1 true PL428534A1 (pl) 2020-07-13
PL245223B1 PL245223B1 (pl) 2024-06-03

Family

ID=71512372

Family Applications (1)

Application Number Title Priority Date Filing Date
PL428534A PL245223B1 (pl) 2019-01-10 2019-01-10 Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna go zawierająca

Country Status (8)

Country Link
US (1) US12478679B2 (pl)
EP (1) EP3908320A4 (pl)
JP (1) JP7654549B2 (pl)
CN (1) CN113301887A (pl)
BR (1) BR112021013680A2 (pl)
CA (1) CA3126384C (pl)
PL (1) PL245223B1 (pl)
WO (1) WO2020145833A1 (pl)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4296104A (en) * 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
PL162918B1 (pl) * 1990-08-20 1994-01-31 Eleonora Macioch Podloze do masci leczniczych i kremów kosmetycznych oraz sposób wytwarzania podloza do masci leczniczych i kremów kosmetycznych PL
US5874479A (en) * 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
US5814659A (en) * 1996-04-23 1998-09-29 Dtr Dermal Therapy (Barbados) Inc. Topical analgesic composition
JPH1072312A (ja) * 1996-09-02 1998-03-17 Shiseido Co Ltd 皮膚外用剤
US6248343B1 (en) * 1998-01-20 2001-06-19 Ethicon, Inc. Therapeutic antimicrobial compositions
US6417227B1 (en) * 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
JP2004075632A (ja) * 2002-08-21 2004-03-11 Noevir Co Ltd 真皮線維芽細胞賦活剤
US20040175415A1 (en) * 2003-03-05 2004-09-09 Chan Alvin C. Formulations and methods of delivery of intact tocopheryl succinate to humans
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
WO2005027977A2 (en) * 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
US7582307B2 (en) * 2003-11-26 2009-09-01 Harmony Labs, Inc. Dermatological composition
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
US20060058387A1 (en) * 2004-09-15 2006-03-16 Albert Aebi Composition and method for treating skin conditions
EP1812073A1 (en) * 2004-09-24 2007-08-01 Lipo Chemicals Inc Delivery system for topically applied compounds
DE102006049585A1 (de) 2006-10-22 2008-04-24 Susilo, Rudy, Dr. Nagellack für kosmetische und medizinische Anwendungen
WO2010125470A2 (en) * 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
EP2664327A1 (en) * 2012-05-14 2013-11-20 Almirall S.A. Topical pharmaceutical compositions comprising terbinafide and urea
UA94218U (uk) * 2014-03-21 2014-11-10 Український Науково-Практичний Центр Ендокринної Хірургії, Трансплантації Ендокринних Органів І Тканин Моз України Речовина для місцевого застосування з антиандрогенним ефектом

Also Published As

Publication number Publication date
CA3126384C (en) 2023-10-24
CN113301887A (zh) 2021-08-24
WO2020145833A1 (en) 2020-07-16
US20220062422A1 (en) 2022-03-03
CA3126384A1 (en) 2020-07-16
EP3908320A1 (en) 2021-11-17
JP7654549B2 (ja) 2025-04-01
BR112021013680A2 (pt) 2021-10-05
EP3908320A4 (en) 2022-09-14
JP2022517613A (ja) 2022-03-09
US12478679B2 (en) 2025-11-25
PL245223B1 (pl) 2024-06-03

Similar Documents

Publication Publication Date Title
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
NI201800139A (es) Formulación farmacéutica líquida estable
AR102198A1 (es) Proceso para reducir partículas subvisibles en una formulación farmacéutica
SA523450367B1 (ar) Magl مثبطات faah و مزدوجة
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
CL2018003178A1 (es) Composición farmacéutica
MY193913A (en) Stable Protein Solution Formulation Containing High Concentration of an Anti-Vegf Antibody
EA201890584A1 (ru) Новые аналоги инсулина и их применение
EA201200728A1 (ru) Новые сокристаллы агомелатина, способ их получения и фармацевтические композиции, которые их содержат
MX2019009894A (es) Uso de una composición alimenticia para reducir la emisión de metano en ruminantes, y para mejorar el rendimiento de los mismos.
EA201791166A1 (ru) Препараты с контролируемым высвобождением
NZ702342A (en) Pharmaceutical formulation
EA202090508A1 (ru) Изготовление фармацевтических составов
PH12018502615A1 (en) Depot formulations
CL2018002548A1 (es) Regulación del metabolismo de ornitina para aumentar el contenido de glicoformas ricas en manosa de proteínas recombinantes.(divisional solicitud 201601786)
EA201700019A1 (ru) Высокочистый оритаванцин и способ его получения
PL428534A1 (pl) Nośnik farmaceutyczny dla substancji czynnych oraz kompozycja farmaceutyczna ją zawierająca
EA201891259A1 (ru) Способ получения алкилового эфира n-ретиноилцистеиновой кислоты
MX2021014310A (es) Formulaciones de terlipressina.
EA202191378A1 (ru) Активные сложноэфирные производные тестостерона, их композиции и применения
BR112017013269A2 (pt) ?composição farmacêutica líquida?
EA201890419A1 (ru) ОТСЕЛЕКТИРОВАННЫЙ АМИД γ-ГИДРОКСИМАСЛЯНОЙ КИСЛОТЫ И ЕГО ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ ЗЛОУПОТРЕБЛЕНИЯ АЛКОГОЛЕМ
EA202091870A1 (ru) Антиперспирантные композиции, не содержащие алюминия
FR3089761B1 (fr) Composition liquide de cigarette électronique
EA201991594A1 (ru) Депо-препарат